Elena Violari, MD, RPVI, discusses irreversible electroporation for pancreatic cancer with Govindarajan Narayanan, MD, in the latest episode of the SIO Corner podcast.
NPWT continues to play a significant role in wound/ulcer management protocols throughout the continuum of care. However, confusion reigns regarding who Medicare will separately pay to provide and apply the equipment and supplies.
A study published in JAMA Oncology found that Black women are more likely to receive false negative results from transvaginal ultrasounds for endometrial cancer compared to White women, highlighting the need for improved diagnostic methods...
A study published in JAMA Oncology found that Black women are more likely to receive false negative results from transvaginal ultrasounds for endometrial cancer compared to White women, highlighting the need for improved diagnostic methods...
On October 15, 2024, the FDA granted approval to the Optune Lua, a wearable device that delivers Tumor Treating Fields, for treatment of patients with metastatic non-small cell lung cancer.
On October 15, 2024, the FDA granted approval to the Optune Lua, a wearable device that delivers Tumor Treating Fields, for treatment of patients with metastatic non-small cell lung cancer.
XYRA Press Release
Key points:
Wearable AF monitoring devices are extensively used in routine practice worldwide.
The FDA has agreed on the use of AF monitoring devices in clinical trials for budiodarone approval.
The FDA...
XYRA Press Release
Key points:
Wearable AF monitoring devices are extensively used in routine practice worldwide.
The FDA has agreed on the use of AF monitoring devices in clinical trials for budiodarone approval.
The FDA...
COVID-19 mRNA vaccine dosing intervals significantly impact the risk of myocarditis, with longer intervals generally associated with lower risk, particularly in younger individuals and males, according to a study published in Nature...
COVID-19 mRNA vaccine dosing intervals significantly impact the risk of myocarditis, with longer intervals generally associated with lower risk, particularly in younger individuals and males, according to a study published in Nature...
All lots of Vail-Bon Jie Yang Wan capsules from 123Herbals are under a Class I recall for being tainted with the undeclared dexamethasone and chlorpheniramine.
All lots of Vail-Bon Jie Yang Wan capsules from 123Herbals are under a Class I recall for being tainted with the undeclared dexamethasone and chlorpheniramine.
Monlunabant was associated with statistically significant weight loss, but the drug was also linked with mild to moderate neuropsychiatric side effects.
Monlunabant was associated with statistically significant weight loss, but the drug was also linked with mild to moderate neuropsychiatric side effects.
Apitegromab, an investigational muscle-targeted therapy, improved motor function in patients with spinal muscular atrophy (SMA), late-stage biopharmaceutical company Scholar Rock recently announced.
Apitegromab, an investigational muscle-targeted therapy, improved motor function in patients with spinal muscular atrophy (SMA), late-stage biopharmaceutical company Scholar Rock recently announced.
Dr Craig Chepke discusses his aspirations in his new role, shares insights from his career journey, and reflects on the impact of Psych Congress events on his clinical practice.
Dr Craig Chepke discusses his aspirations in his new role, shares insights from his career journey, and reflects on the impact of Psych Congress events on his clinical practice.
At the 2024 SGO Annual Meeting on Women’s Cancers, Bradley Corr, MD, discusses the results from a study evaluating rucaparib maintenance therapy for patients with metastatic or recurrent endometrial cancer.
At the 2024 SGO Annual Meeting on Women’s Cancers, Bradley Corr, MD, discusses the results from a study evaluating rucaparib maintenance therapy for patients with metastatic or recurrent endometrial cancer.
Jing-Zhou Hou, MD, PhD, discusses how the standard of care for CLL has evolved among community oncologists since 2020 and how clinical and demographic factors impact treatment selection.
Jing-Zhou Hou, MD, PhD, discusses how the standard of care for CLL has evolved among community oncologists since 2020 and how clinical and demographic factors impact treatment selection.
At the 2024 SIO Annual Meeting, Jack Jennings, MD, PhD, discussed the role of the interventional oncologist when treating primary or metastatic sarcomas of the bone or soft tissue.
At the 2024 SIO Annual Meeting, Jack Jennings, MD, PhD, discussed the role of the interventional oncologist when treating primary or metastatic sarcomas of the bone or soft tissue.
Saby George shares insights from the CheckMate 67T evaluating the subcutaneous administration of nivolumab for patients with clear cell renal cell carcinoma, compared with the intravenous administration.
Saby George shares insights from the CheckMate 67T evaluating the subcutaneous administration of nivolumab for patients with clear cell renal cell carcinoma, compared with the intravenous administration.
Michiel van der Heijden, MD, discusses the subgroup analyses of the phase 3 EV-302 study, evaluating enfortumab vedotin plus pembrolizumab among patients with locally advanced or metastatic urothelial carcinoma in the first-line setting.
Michiel van der Heijden, MD, discusses the subgroup analyses of the phase 3 EV-302 study, evaluating enfortumab vedotin plus pembrolizumab among patients with locally advanced or metastatic urothelial carcinoma in the first-line setting.
Thierry Andre, MD, discusses the first results from the CheckMate 8HW study exploring nivolumab plus chemotherapy for the first-line treatment of microsatellite instability-high, mismatch repair-deficient metastatic colorectal cancer.
Thierry Andre, MD, discusses the first results from the CheckMate 8HW study exploring nivolumab plus chemotherapy for the first-line treatment of microsatellite instability-high, mismatch repair-deficient metastatic colorectal cancer.
Ricardo Lencioni, MD, shares results from the phase 3 EMERALD-1 study which found the addition of durvalumab and bevacizumab to TACE improved progression-free survival among patients with hepatocellular carcinoma, compared with TACE alone.
Ricardo Lencioni, MD, shares results from the phase 3 EMERALD-1 study which found the addition of durvalumab and bevacizumab to TACE improved progression-free survival among patients with hepatocellular carcinoma, compared with TACE alone.